Skip to main content

Specialty Pharmacy

  • Gilead Sciences acquires Pharmasset for $11 billion

    FOSTER CITY, Calif. — Drug maker Gilead Sciences will acquire Pharmasset for $11 billion, or $137 per share, Gilead said Monday.

    Pharmasset, based in Princeton, N.J., is a drug maker that currently has three treatments for hepatitis C undergoing clinical trials, including PSI-7977, which is in late-stage development.

  • FDA approves Erwinaze for acute lymphoblastic leukemia

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new chemotherapy drug for treating acute lymphoblastic leukemia, the agency said Friday.

    The FDA announced the approval of EUSA Pharma's Erwinaze (asparaginase Erwinia chrysanthemi) to treat patients with ALL who have developed an allergy to E. coli-derived asparaginase and pegaspargase chemotherapy drugs.

  • FDA revokes breast cancer approval for Avastin

    SILVER SPRING, Md. — A drug widely used to treat breast cancer is not safe or effective, the Food and Drug Administration said Friday.

  • Need for more convenient therapies, competition from generics, biosimilars spurs RA drug development

    MOUNTAIN VIEW, Calif. — The increase in the number of people with rheumatoid arthritis, and the challenges posed to drug makers by generics, is encouraging the development of new drugs for the disease, according to a new report by Frost & Sullivan.

  • Former Mercer executive named president of CVS Caremark's Accordant business

    WOONSOCKET, R.I. — CVS Caremark has appointed Kevin Murphy president for Accordant Health Services, a CVS Caremark company that provides disease management and case management services for people with rare chronic conditions.

    Murphy is in charge of integrating the company's leading rare disease management programs with its specialty pharmacy programs and new focus on medical pharmacy management.

  • FDA approves drug for rare bone marrow disorder

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating a rare bone marrow disease, the agency said Wednesday.

  • Walgreens general counsel named to Unigene board

    BOONTON, N.J. — Unigene Labs, a developer of peptide-based therapeutics, on Wednesday appointed Walgreens' Thomas Sabatino Jr. to its board of directors.

    "[Sabatino's] extensive industry experience and impressive track record — specifically, his knowledge of the legal and regulatory landscape for pharmaceutical companies — will be invaluable as Unigene continues to execute against its business transformation," Unigene chairman Richard Levy said.

  • DSN From The Blogs: Ideas are your products, too

    NEW YORK — Ideas are just as important to a winning company’s overall success as the products and services it sells. So, what’s your company doing to create a culture where the ideas that create your products and services are as important as the products themselves? That’s the question Dan Mack — EVP strategic business development for The Swanson Group and founder of the Mack Elevation Forum — puts to DrugStoreNews.com users in a hot, new content feature that debuted this week on DrugStoreNews.com.

X
This ad will auto-close in 10 seconds